Ligand’s First Quarter Financial Results to be Reported May 6th
April 22 2020 - 8:30AM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
provided today details of its plans to report first quarter 2020
financial results on May 6, 2020. Ligand’s CEO John Higgins,
President and COO Matt Foehr and Executive Vice President and CFO
Matt Korenberg will host the conference call.
What:
Ligand conference call to discuss
financial results and provide general business updates
Date:
Wednesday, May 6, 2020
Time:
4:30 p.m. Eastern time (1:30 p.m. Pacific
time)
Conference Call:
Dial (833) 325-0071 within the U.S.
Dial (720) 405-1612 outside the U.S.
Conference ID is 5190682
Webcast:
Live conference call webcast and replay
accessible at www.ligand.com
About Ligand Pharmaceuticals
Ligand is a revenue generating biopharmaceutical company focused
on developing or acquiring technologies that help pharmaceutical
companies discover and develop medicines. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
OmniAb® technology platform is a patent-protected transgenic animal
platform used in the discovery of fully human mono- and bispecific
therapeutic antibodies. The Captisol platform technology is a
patent-protected, chemically modified cyclodextrin with a structure
designed to optimize the solubility and stability of drugs. The
Vernalis Design Platform (VDP) integrates protein structure
determination and engineering, fragment screening and molecular
modeling, with medicinal chemistry, to help enable success in novel
drug discovery programs against highly-challenging targets. Ligand
has established multiple alliances, licenses and other business
relationships with the world’s leading pharmaceutical companies
including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Gilead
Sciences and Roche. For more information, please visit
www.ligand.com.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200422005213/en/
Ligand Pharmaceuticals Incorporated Patrick O'Brien Email:
investors@ligand.com Phone: (858)
550-7893 Twitter: @Ligand_LGND
LHA Investor Relations Bruce Voss Email: bvoss@lhai.com Phone: (310) 691-7100
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Sep 2023 to Sep 2024